SG Americas Securities LLC Makes New $488,000 Investment in AtriCure, Inc. (NASDAQ:ATRC)

SG Americas Securities LLC bought a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 17,393 shares of the medical device company’s stock, valued at approximately $488,000.

Several other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of AtriCure by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 4,766,029 shares of the medical device company’s stock valued at $170,100,000 after acquiring an additional 76,146 shares in the last quarter. Champlain Investment Partners LLC boosted its position in shares of AtriCure by 27.3% during the 1st quarter. Champlain Investment Partners LLC now owns 2,681,000 shares of the medical device company’s stock valued at $81,556,000 after acquiring an additional 575,605 shares in the last quarter. First Light Asset Management LLC boosted its position in shares of AtriCure by 42.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company’s stock valued at $44,736,000 after acquiring an additional 581,843 shares in the last quarter. Hood River Capital Management LLC acquired a new stake in shares of AtriCure during the 2nd quarter valued at about $40,422,000. Finally, Wellington Management Group LLP boosted its position in shares of AtriCure by 7.8% during the 4th quarter. Wellington Management Group LLP now owns 1,329,457 shares of the medical device company’s stock valued at $47,448,000 after acquiring an additional 95,824 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at AtriCure

In related news, Director Maggie Yuen sold 3,500 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $24.07, for a total value of $84,245.00. Following the transaction, the director now directly owns 8,970 shares in the company, valued at $215,907.90. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.20% of the stock is currently owned by company insiders.

AtriCure Price Performance

Shares of ATRC stock opened at $29.16 on Thursday. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.00. The firm’s 50 day moving average is $26.38 and its 200-day moving average is $24.17. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -36.45 and a beta of 1.44. The company has a current ratio of 4.13, a quick ratio of 2.93 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). AtriCure had a negative net margin of 9.33% and a negative return on equity of 8.39%. The business had revenue of $116.27 million for the quarter, compared to analyst estimates of $116.24 million. During the same period in the prior year, the business posted ($0.12) earnings per share. AtriCure’s revenue was up 15.2% compared to the same quarter last year. Sell-side analysts forecast that AtriCure, Inc. will post -0.77 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of AtriCure from $34.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. BTIG Research cut their price target on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. StockNews.com raised shares of AtriCure from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. Needham & Company LLC cut their price target on shares of AtriCure from $40.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Piper Sandler cut their price target on shares of AtriCure from $65.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.44.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.